Cost Utility Analysis of 177Lu-PSMA-617 Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC) in Germany

被引：0
|
作者：
Stargardt, T. [1 ]
Brinkmann, C. [1 ]
Baum, R. P. [2 ,3 ]
机构：
[1] Univ Hamburg, Hamburg Ctr Hlth Econ, Hamburg, Germany
[2] Int Ctr Precis Oncol ICPO, Wiesbaden, Germany
[3] CURANOSTICUM, Wiesbaden, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2024年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EP-0988
引用
收藏
页码：S827 / S827
页数：1
相关论文
共 50 条
  • [41] Hematotoxicity after radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617
    Zimbelmann, Stefanie
    Eppard, Elisabeth
    Hauser, Stefan
    Kuerpig, Stefan
    Yordanova, Anna
    Essler, Markus
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [42] Phase 3 Study of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer (VISION)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (08) : 3 - 5
  • [43] Phase 3 Study of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer (VISION)
    Krause, B.
    de Bono, J.
    Chi, K. N.
    Fizazi, K.
    Herrmann, K.
    Rahbar, K.
    Tagawa, S. T.
    Nordquist, L. T.
    Vaishampayan, N.
    El-Haddad, G.
    Park, C. H.
    Beer, T. M.
    Perez-Contreras, W. J.
    DeSilvio, M.
    Kpamegan, E.
    Gericke, G.
    Messmann, R. A.
    Morris, M. J.
    Sartor, O.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S63 - S63
  • [44] Dosimetry of 177Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: A substudy of the VISION trial
    Kurth, Jens
    Herrmann, Ken
    Eiber, Matthias
    Rahbar, Kambiz
    Heuschkel, Martin
    Lassmann, Michael
    Jentzen, Walter
    Chicco, Daniela
    Messmann, Richard
    Sartor, A. Oliver
    Morris, Michael J.
    Krause, Bernd J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [45] Final results of phase I/II trial of fractionated dose 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC)
    Tagawa, S. T.
    Sun, M.
    Sartor, O.
    Thomas, C.
    Molina, A. M.
    Sternberg, C. N.
    Nanus, D. M.
    Osborne, J.
    Bander, N.
    ANNALS OF ONCOLOGY, 2021, 32 : S645 - S645
  • [46] 177Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer
    von Eyben, Finn E.
    Kiljunen, Timo
    Joensuu, Timo
    Kairemo, Kalevi
    Uprimny, Christian
    Virgolini, Irene
    ONCOTARGET, 2017, 8 (39) : 66112 - 66116
  • [47] Treatment of castration-resistant metastatic prostate cancer with [177Lu]PSMA radioligand
    Sundset, Rune
    Haugnes, Hege Sagstuen
    Perez, Alexander
    Engelsen, Ola
    Fosseide, Ida H. H.
    Castillejo, Miguel J.
    Bogsrud, Trond Velde
    TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING, 2024, 144 (09)
  • [48] Lu-177 PSMA Radioligand Therapy as Salvage Treatment in Metastatic Castration-Resistant Prostate Cancer
    Kulkarni, H. R.
    Singh, A.
    Schuchardt, C.
    Langbein, T.
    Zhang, J.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S287 - S288
  • [49] Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients
    Yadav, Madhav
    Ballal, Sanjana
    Bal, Chandrasekhar
    Tripathi, Madhavi
    Damle, Nishikant
    Shamim, Shamim Ahmed
    Kumar, Rakesh
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62
  • [50] Personalized dosimetry assessment of [177Lu]Lu-PSMA-617 radioligand therapy in the management of metastatic castration-resistant prostate cancer
    Kazemi-Jahromi, Mahmood
    Yazdani, Elmira
    Karamzade-Ziarati, Najme
    Asadi, Mahboobeh
    Sadeghi, Mahdi
    Geramifar, Parham
    INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2024, 100 (11) : 1551 - 1559
12345